Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.

•Pirfenidone and nintedanib are the mostly used anti-fibrotic drugs for idiopathic pulmonary fibrosis (IPF).•Face to face, randomized controlled and real life studies are lacking.•In real life both drugs are effective in reducing the 24-month decline of Forced Vital Capacity and Diffusing Lung Capacity.•Sicker patients in both groups were likely to show a more rapid decline in respiratory function.